NMD Pharma A/S — Credit Rating and Financial Key Figures
CVR number: 36899069
Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
Income statement (kEUR)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -7 086.63 | -7 870.12 | -11 029.05 | -9 480.44 | -19 182.08 |
| Employee benefit expenses | -2 058.53 | -2 743.00 | -3 223.88 | -3 499.79 | -4 039.65 |
| Total depreciation | -18.92 | ||||
| EBIT | -9 145.17 | -10 613.13 | -14 252.93 | -12 980.23 | -23 240.65 |
| Other financial income | 107.50 | ||||
| Other financial expenses | -92.67 | -51.46 | -97.72 | -80.32 | -4.84 |
| Pre-tax profit | -9 237.83 | -10 664.59 | -14 350.64 | -13 060.55 | -23 138.00 |
| Income taxes | 736.56 | 736.56 | 736.56 | 736.56 | 736.56 |
| Net earnings | -8 501.27 | -9 928.03 | -13 614.08 | -12 323.99 | -22 401.44 |
Assets (kEUR)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 94.61 | 160.60 | |||
| Tangible assets total | 94.61 | 160.60 | |||
| Holdings in group member companies | 0.00 | 0.00 | |||
| Investments total | 0.00 | 0.00 | |||
| Non-current other receivables | 76.97 | 80.91 | 82.61 | 121.29 | |
| Long term receivables total | 76.97 | 80.91 | 82.61 | 121.29 | |
| Inventories total | |||||
| Current amounts owed by group member comp. | 67.94 | ||||
| Prepayments and accrued income | 14.98 | 16.93 | 36.16 | ||
| Current other receivables | 136.02 | 1 226.03 | 286.45 | 319.04 | 277.58 |
| Current deferred tax assets | 736.56 | 736.56 | 736.56 | 736.56 | 736.56 |
| Short term receivables total | 887.56 | 1 962.59 | 1 023.01 | 1 140.48 | 1 050.31 |
| Cash and bank deposits | 9 177.32 | 9 448.99 | 3 815.83 | 25 820.86 | 45 060.42 |
| Cash and cash equivalents | 9 177.32 | 9 448.99 | 3 815.83 | 25 820.86 | 45 060.42 |
| Balance sheet total (assets) | 10 064.88 | 11 488.55 | 4 919.75 | 27 138.56 | 46 392.63 |
Equity and liabilities (kEUR)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 140.24 | 192.93 | 226.46 | 394.10 | 576.55 |
| Retained earnings | 16 572.17 | 18 978.22 | 15 983.20 | 37 062.85 | 64 497.75 |
| Profit of the financial year | -8 501.27 | -9 928.03 | -13 614.08 | -12 323.99 | -22 401.44 |
| Shareholders equity total | 8 211.13 | 9 243.12 | 2 595.58 | 25 132.97 | 42 672.87 |
| Non-current other liabilities | 63.45 | 201.31 | 201.31 | ||
| Non-current liabilities total | 63.45 | 201.31 | 201.31 | ||
| Current loans from credit institutions | 29.29 | 12.16 | 14.59 | 31.81 | 18.14 |
| Current trade creditors | 1 465.47 | 1 446.57 | 1 669.17 | 1 526.02 | 3 016.39 |
| Current owed to group member | 76.80 | ||||
| Other non-interest bearing current liabilities | 295.53 | 585.39 | 439.10 | 447.77 | 608.42 |
| Current liabilities total | 1 790.29 | 2 044.12 | 2 122.85 | 2 005.60 | 3 719.75 |
| Balance sheet total (liabilities) | 10 064.88 | 11 488.55 | 4 919.75 | 27 138.56 | 46 392.63 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.